{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T23:46:47Z","timestamp":1782172007728,"version":"3.54.5"},"reference-count":27,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate current pharmacotherapeutic strategies for H3 K27M-mutant diffuse midline glioma (DMG), with emphasis on the clinical evidence for dordaviprone, its place in therapy, and its implications for oncology practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction<\/jats:title>\n                    <jats:p>A structured literature search was conducted using PubMed and ClinicalTrials.gov through November 1, 2025. The search terms \u201c(ONC201 OR dordaviprone) AND (\u2018diffuse midline glioma\u2019 OR DMG OR H3 K27\u2005M OR H3K27-altered)\u201d were applied using Boolean operators. Clinical trials, cohort studies, case reports, and relevant preclinical studies evaluating pharmacologic therapies in H3 K27\u2005M DMG were included, with emphasis on clinical outcomes and safety. The review was informed by PRISMA principles and conducted as a narrative review given the limited evidence base. A full systematic review was not possible given the limited and heterogeneous evidence base.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Dordaviprone received accelerated FDA approval based on the results of an integrative analysis of five phase 1 and 2 trials. The primary endpoint of overall response rate (ORR) was 20%, disease control rate 40%, and median duration of response (DOR) was 11.2 months. Fatigue, headache, vomiting, and nausea are the most common adverse effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Dordaviprone is the only FDA approved medication for H3 K27\u2005M DMG. It demonstrates long-lasting radiographic and symptomatic improvement. It is currently approved for recurrence following prior therapy, not as a substitute for radiation or surgery. The ACTION trial may provide guidance on its broader use in newly diagnosed H3 K27\u2005M DMG. Pharmacists play a role in optimizing treatment, monitoring safety and drug interactions, and supporting patient adherence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Dordaviprone is a novel treatment option with modest response rates and durable benefit in recurrent\/progressive H3 K27\u2005M DMG. Ongoing trials may further define its role in earlier lines of therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552261461529","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T08:12:57Z","timestamp":1781856777000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["H3K27M-mutant diffuse midline glioma pharmacotherapy: Clinical evidence and practice implications of dordaviprone"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2291-0448","authenticated-orcid":false,"given":"Zachary J","family":"Nuss","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Infectious Disease Consultants"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"DeYoung","sequence":"additional","affiliation":[{"name":"University of Kansas School of Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derick","family":"Gross","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Wesley Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"e_1_3_2_2_2","article-title":"New progress in the treatment of diffuse midline glioma with H3 K27\u2005M alteration","volume":"10","author":"Yang Z","unstructured":"Yang Z, Sun L, Chen H, et al. New progress in the treatment of diffuse midline glioma with H3 K27\u2005M alteration. Heliyon 2024 Jan 18; 10: e24877.","journal-title":"Heliyon"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa106"},{"key":"e_1_3_2_4_2","unstructured":"Modeyso (dordaviprone) [package insert]. Palo Alto CA USA: Jazz Pharmaceuticals Inc.; 2025."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01134"},{"key":"e_1_3_2_7_2","unstructured":"United States Food and Drug Administration. FDA grants accelerated approval to dordaviprone for diffuse midline glioma. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-dordaviprone-diffuse-midline-glioma. Accessed October 20 2025."},{"key":"e_1_3_2_8_2","first-page":"592","article-title":"ACTION Trial: a randomized phase 3 study of ONC201 in newly diagnosed diffuse midline glioma","volume":"26","author":"Kline CN","year":"2024","unstructured":"Kline CN, Himes BT, Chen J, et al. ACTION Trial: a randomized phase 3 study of ONC201 in newly diagnosed diffuse midline glioma. Neuro Oncol 2024; 26: 592\u2013603.","journal-title":"Neuro Oncol"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1512"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/bcp.70080"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01059"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.44.4.675"},{"key":"e_1_3_2_13_2","first-page":"673","article-title":"Pharmacokinetics and pharmacodynamics of betamethasone in humans","volume":"87","author":"Poon W","year":"2021","unstructured":"Poon W, Liu M, Li W, et al. Pharmacokinetics and pharmacodynamics of betamethasone in humans. Br J Clin Pharmacol 2021; 87: 673\u2013683. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7778726\/","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2008.12.032"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.2176\/nmccrj.cr.2021-0033"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.3390\/tomography10090110"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-017-0500-2"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043331"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noq205"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.2176\/nmc.ra.2018-0044"},{"key":"e_1_3_2_21_2","first-page":"1013","article-title":"GD2-targeted CAR T cells mediate clinical and biologic activity in diffuse midline gliomas","volume":"30","author":"Majzner RG","year":"2024","unstructured":"Majzner RG, Lam N, Klinger M, et al. GD2-targeted CAR T cells mediate clinical and biologic activity in diffuse midline gliomas. Nat Med 2024; 30: 1013\u20131023. PMID: 38771986.","journal-title":"Nat Med"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2124058"},{"key":"e_1_3_2_23_2","first-page":"145","article-title":"Mebendazole synergizes with radiation in diffuse midline glioma models","volume":"27","author":"Wang J","year":"2025","unstructured":"Wang J, Liu H, Xu J, et al. Mebendazole synergizes with radiation in diffuse midline glioma models. Neuro Oncol 2025; 27: 145\u2013156. PMID: 40667566.","journal-title":"Neuro Oncol"},{"key":"e_1_3_2_24_2","first-page":"1170","article-title":"Venetoclax enhances the efficacy of radiation in glioblastoma models","volume":"21","author":"Coss D","year":"2022","unstructured":"Coss D, Jiang H, Caruso FP, et al. Venetoclax enhances the efficacy of radiation in glioblastoma models. Mol Cancer Ther 2022; 21: 1170\u20131181. PMID: 35344040.","journal-title":"Mol Cancer Ther"},{"key":"e_1_3_2_25_2","first-page":"89","article-title":"CD99 Expression promotes malignancy and therapeutic resistance in diffuse midline glioma","volume":"163","author":"Zhang Q","year":"2025","unstructured":"Zhang Q, Liu Y, Wang J, et al. CD99 Expression promotes malignancy and therapeutic resistance in diffuse midline glioma. J Neurooncol 2025; 163: 89\u2013101. PMID: 40424183.","journal-title":"J Neurooncol"},{"key":"e_1_3_2_26_2","first-page":"3409","article-title":"Anlotinib for recurrent diffuse midline glioma: a case report","volume":"11","author":"Chen H","year":"2022","unstructured":"Chen H, Zhao J, Liu Z, et al. Anlotinib for recurrent diffuse midline glioma: a case report. Transl Cancer Res 2022; 11: 3409\u20133414.","journal-title":"Transl Cancer Res"},{"key":"e_1_3_2_27_2","first-page":"731","article-title":"Olaparib in combination therapy for diffuse midline glioma: a case report","volume":"40","author":"Montano N","year":"2022","unstructured":"Montano N, D\u2019Alessandris QG, Di Bonaventura R, et al. Olaparib in combination therapy for diffuse midline glioma: a case report. Invest New Drugs 2022; 40: 731\u2013736.","journal-title":"Invest New Drugs"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP-25-00233"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261461529","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552261461529","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261461529","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T22:49:54Z","timestamp":1782168594000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552261461529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":27,"alternative-id":["10.1177\/10781552261461529"],"URL":"https:\/\/doi.org\/10.1177\/10781552261461529","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"article-number":"10781552261461529"}}